30 Ağustos 2021 Dergi makalesi Açık Erişim

Mehmet; Gökhan; Pamir

JSON-LD (schema.org)

{
  "@context": "https://schema.org/", 
  "@id": 227983, 
  "@type": "ScholarlyArticle", 
  "creator": [
    {
      "@id": "https://orcid.org/0000-0003-1710-7018", 
      "@type": "Person", 
      "affiliation": "SOY", 
      "name": "Mehmet"
    }, 
    {
      "@id": "https://orcid.org/0000-0001-7289-1816", 
      "@type": "Person", 
      "affiliation": "KESER", 
      "name": "G\u00f6khan"
    }, 
    {
      "@id": "https://orcid.org/0000-0002-6393-7461", 
      "@type": "Person", 
      "affiliation": "ATAG\u00dcND\u00dcZ", 
      "name": "Pamir"
    }
  ], 
  "datePublished": "2021-08-30", 
  "description": "<p>COVID-19 is a viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that killed a large&nbsp;number of patients around the world. A hyperinflammatory state resulting in a cytokine storm and adult respiratory distress syndrome&nbsp;seems to be the major cause of the death. Many mechanisms have been suggested in the pathogenesis of COVID-19 associated cytokine&nbsp;storm (COVID-CS). Insufficient viral clearance and persistence of a strong cytokine response despite inadequate antiviral immunity&nbsp;seem to be the main mechanisms underlying the pathogenesis. The diagnosis of COVID-19 is based on relatively constant clinical&nbsp;symptoms, clinical findings, laboratory tests, and imaging techniques, while the diagnosis of COVID-CS is a rather dynamic process,&nbsp;based on evolving or newly emerging findings during the clinical course. Management of COVID-19 consists of using antiviral agents&nbsp;to inhibit SARS-CoV-2 replication and treating potential complications including the cytokine storm together with general supportive&nbsp;measures. COVID-CS may be treated using appropriate immunosuppressive and immunomodulatory drugs that reduce the level of&nbsp;inappropriate systemic inflammation, which has the potential to cause organ damage. Currently corticosteroids, IL-6 blockers, or IL-1&nbsp;blockers are most widely used for treating COVID-CS.</p>", 
  "headline": "Pathogenesis and treatment of cytokine storm in COVID-19", 
  "identifier": 227983, 
  "image": "https://aperta.ulakbim.gov.tr/static/img/logo/aperta_logo_with_icon.svg", 
  "keywords": [
    "COVID-19", 
    "SARS-CoV-2", 
    "cytokine storm", 
    "acute respiratory distress syndrome", 
    "tocilizumab", 
    "anakinra"
  ], 
  "license": "http://www.opendefinition.org/licenses/cc-by-sa", 
  "name": "Pathogenesis and treatment of cytokine storm in COVID-19", 
  "url": "https://aperta.ulakbim.gov.tr/record/227983"
}